No label defined (Q33268)
Jump to navigation
Jump to search
No description defined
- Impact of hormonal therapy on HIV-1 immune markers in cis women and gender minorities.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
No description defined |
|
Statements
Although sex hormones are recognized to induce immune variations, the effect of hormonal therapy use on immunity is only poorly understood. (English)
© 2024 The Author(s). HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. (English)
2024
Here, we quantified how hormonal therapy use affects HIV-1 immune markers in cis women (CW) and trans women and non-binary people (TNBP) with HIV. (English)
© 2024 The Author(s). HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. (English)
2024
We considered CD4, CD8 and lymphocyte measurements from cis men (CM), CW and TNBP in the Swiss HIV Cohort Study. (English)
© 2024 The Author(s). HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. (English)
2024
We modelled HIV-1 markers using linear mixed-effects models with an interaction between 'gender' (CW, TNBP) and 'hormonal therapy use' (yes/no). (English)
© 2024 The Author(s). HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. (English)
2024
Models were adjusted on age, ethnicity, education level, time since start of antiretroviral therapy and use of intravenous drugs. (English)
© 2024 The Author(s). HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. (English)
2024
We assessed the inflammatory effect of hormonal therapy use in 31 TNBP using serum proteomics measurements of 92 inflammation markers. (English)
© 2024 The Author(s). HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. (English)
2024
We included 54 083 measurements from 3092 CW and 83 TNBP, and 147 230 measurements from 8611 CM. (English)
© 2024 The Author(s). HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. (English)
2024
Hormonal therapy use increased CD4 count and CD4:CD8 ratio in TNBP more than in CW (p<sub>interaction</sub> = 0.02 and 0.007, respectively). (English)
© 2024 The Author(s). HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. (English)
2024
TNBP with hormonal therapy use had significantly higher CD4 counts [median = 772 cells/μL, interquartile range (IQR): 520-1006] than without (617 cells/μL, 426-892). (English)
© 2024 The Author(s). HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. (English)
2024
This was similar to the effect of CW versus CM on CD4 T cells. (English)
© 2024 The Author(s). HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. (English)
2024
Hormonal therapy use did not affect serum protein concentrations in TNBP. (English)
© 2024 The Author(s). HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. (English)
2024
This study highlights the potential role of hormonal therapy use in modulating the immune system among other biological and social factors, especially in TNBP with HIV. (English)
© 2024 The Author(s). HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. (English)
2024
Chloé (English)
Pasin (English)
C
David Garcia (English)
Nuñez (English)
DG
Katharina (English)
Kusejko (English)
K
Anna (English)
Hachfeld (English)
A
Hélène (English)
Buvelot (English)
H
Matthias (English)
Cavassini (English)
M
Lauro (English)
Damonti (English)
L
Christoph (English)
Fux (English)
C
Begoña Martinez (English)
de Tejada (English)
BM
Julia (English)
Notter (English)
J
Alexandra (English)
Trkola (English)
A
Huldrych F (English)
Günthard (English)
HF
Karoline (English)
Aebi-Popp (English)
K
Roger D (English)
Kouyos (English)
RD
Irene A (English)
Abela (English)
IA
I (English)
Abela (English)
I
K (English)
Aebi-Popp (English)
K
A (English)
Anagnostopoulos (English)
A
M (English)
Battegay (English)
M
E (English)
Bernasconi (English)
E
D L (English)
Braun (English)
DL
H C (English)
Bucher (English)
HC
A (English)
Calmy (English)
A
M (English)
Cavassini (English)
M
A (English)
Ciuffi (English)
A
G (English)
Dollenmaier (English)
G
M (English)
Egger (English)
M
L (English)
Elzi (English)
L
J (English)
Fehr (English)
J
J (English)
Fellay (English)
J
H (English)
Furrer (English)
H
C A (English)
Fux (English)
CA
H F (English)
Günthard (English)
HF
A (English)
Hachfeld (English)
A
D (English)
Haerry (English)
D
B (English)
Hasse (English)
B
H H (English)
Hirsch (English)
HH
M (English)
Hoffmann (English)
M
I (English)
Hösli (English)
I
M (English)
Huber (English)
M
D (English)
Jackson-Perry (English)
D
C R (English)
Kahlert (English)
CR
L (English)
Kaiser (English)
L
O (English)
Keiser (English)
O
T (English)
Klimkait (English)
T
R D (English)
Kouyos (English)
RD
H (English)
Kovari (English)
H
K (English)
Kusejko (English)
K
N (English)
Labhardt (English)
N
K (English)
Leuzinger (English)
K
B (English)
Martinez de Tejada (English)
B
C (English)
Marzolini (English)
C
K J (English)
Metzner (English)
KJ
N (English)
Müller (English)
N
J (English)
Nemeth (English)
J
D (English)
Nicca (English)
D
J (English)
Notter (English)
J
P (English)
Paioni (English)
P
G (English)
Pantaleo (English)
G
M (English)
Perreau (English)
M
A (English)
Rauch (English)
A
L (English)
Salazar-Vizcaya (English)
L
P (English)
Schmid (English)
P
R (English)
Speck (English)
R
M (English)
Stöckle (English)
M
P (English)
Tarr (English)
P
A (English)
Trkola (English)
A
G (English)
Wandeler (English)
G
M (English)
Weisser (English)
M
S (English)
Yerly (English)
S
18 October 2024
6 October 2024